The cAMP and Ca 2+ signaling pathways activate the transcription factor CREB through its phosphorylation at Serine 133. Activation of CREB is involved in the regulation of various biological phenomena. To understand further the mechanisms of the regulation of CREB activity in response to activation of the cAMP and Ca 2+ signaling pathways, we examined the roles of PLCcs in CREB activation in PC12 cells. siRNA-mediated reduction of the expression of PLCc2, but not PLCc1, inhibited both the phosphorylation of CREB at S133 and the activation of CREB-dependent transcription following treatment of cells with forskolin or ionomycin, which increases the intracellular concentrations of cAMP or Ca 2+ , respectively. Importantly, the siRNA targeting PLCc2 completely abolished CREB activation by Ca 2+ signaling but not by cAMP signaling. These results suggest that PLCc2 functions as an essential signal transducer leading to CREB activation in response to activation of the Ca 2+ signaling pathway and that the cAMP signaling pathway might activate CREB through phosphorylation of CREB by PKA and another signaling pathway mediated by PLCc2.
Introduction
The transcription factor CREB has been shown to regulate various biological phenomena, including memory consolidation, circadian rhythm, spermatogenesis, gluconeogenesis and cell survival (Waeber et al. 1991; Ginty et al. 1993; Ghosh et al. 1994; Sassone-Corsi 1995; Silva et al. 1998; Herzig et al. 2001; Mayr and Montminy 2001a; Kida et al. 2002) . Furthermore, abundant evidence suggests that abnormalities of CREB signaling pathway are involved in the etiology of several diseases, including Rubinstein-Taybi syndrome, Alzheimer's disease and Huntington's disease (Petrij et al. 1995; Marambaud et al. 2003; Obrietan and Hoyt 2004) . PKA and CaMKs phosphorylate CREB on Serine 133 (S133) in response to an increase in the intracellular concentrations of cAMP and Ca 2+ (Gonzalez and Montminy 1989; Sheng et al. 1990; Sheng et al. 1991; Brindle and Montminy 1992; Bito et al. 1996; Schonwasser et al. 1998; Shaywitz and Greenberg 1999; Mayr and Montminy 2001a) . Phosphorylated CREB interacts with the transcriptional coactivator CBP and activates transcription through the cAMP responsive element (CRE) within the promoters of target genes (Chrivia et al. 1993; Kwok et al. 1994; Brindle et al. 1995; Mayr et al. 2001b) . Recent studies have shown that CREB can be phosphorylated on S133 by multiple kinases, such as PKC, RSKs and p70 S6 kinase (Gonzalez and Montminy 1989; de Groot et al. 1993; Xie and Rothstein 1995; Xing et al. 1996; Sung et al. 2001) .
Phosphoinotiside-specific phospholipase C (PLC) catalyzes the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP 2 ) into inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DG) in response to various extracellular signals (Majerus et al. 1986; Rhee and Choi 1992; Berridge 1993; Rebecchi and Pentyala 2000) . IP 3 and DG act as intracellular second messengers, leading to rapid Ca 2+ release from the endoplasmic reticulum (ER) and activation of protein kinase C (PKC), respectively (Nishizuka 1988; Rhee and Choi 1992; Berridge 1993; Rebecchi and Pentyala 2000) . The PLC isozymes have been divided into three families: PLC-b, PLC-c and PLC-d. PLC-b is activated by G proteinactivated receptors (GPCR), whereas PLC-c isoforms (PLC-c1 and PLC-c2) are activated by tyrosine kinase receptors and nonreceptor tyrosine kinases (Rhee and Choi 1992; Berridge 1993; Liao et al. 1993; Park et al. 1993; Rebecchi and Pentyala 2000) . Importantly, PLCcs also potentiate Ca 2+ responses in a lipase-independent manner (Patterson et al. 2002; Nishida et al. 2003) . Additionally, recent studies have demonstrated that PLCcs function as downstream signal transducers of PKAinduced signaling pathways (Yu et al. 1996) .
Previous studies have suggested that PLCcs play important roles in CREB activation (Minichiello et al. 2002) . Indeed, PLC-c1 mediates the phosphorylation of CREB at S133 in response to the activation of tyrosine kinase receptors (trkB) in hippocampal primary neurons (Minichiello et al. 2002) . In this report, to understand the mechanisms of CREB activation by cAMP and Ca 2+ signaling pathways, we examined the roles of PLCcs in cAMP-and Ca 2+ -induced CREB activation in PC12 cells using siRNAs targeting PLCc1 and PLCc2. We found that reduced expression of PLCc2, but not PLC-c1, inhibited both the phosphorylation of CREB at S133 and CREB-dependent transcription in response to activation of cAMP or Ca 2+ signals. These results indicate a critical role for PLC-c2 in CREB activation in PC12 cells.
Materials and methods

Plasmid construction
Full-length cDNAs encoding murine PLCc1 were obtained by reverse transcription (RT)-PCR using mouse brain mRNA as a template. The following oligonucleotides were used as primers for PCR: PLCc1 forward primer, GGGGGATCCACGC-GTATGGAATTCCGCTTGAAGAC; PLCc1 reverse primer, GGGAAGCTTACGCGTCTAGA GGCGGTTGTCTCCAT. The resulting PCR fragment encoding PLCc1 was subcloned into the BamHI-HindIII sites of pCMV-myc (pmyc; CLONTECH, NJ), generating pmyc-PLCc1. To generate GAL4-dependent luciferase reporter plasmid (pGAL4RE-Luc), a 305 bp fragment containing five copies of the GAL4 response element (GAL4RE) and the SV40 minimal promoter was amplified by PCR using pG5CAT vector (CLON-TECH, CA) as a template and the following primers: forward primer, GGGCCATGGACTAGTC TGCAGCTATGACCATGATTACGCGC, and reverse primer, GGGACGCGTAGATCTTTTA GCTTCCTTAGCTCCTG. The resulting PCR fragment was subcloned into the MluI-NcoI sites of pGL3 (Promega, WI). To generate a plasmid expressing GAL4-CREB (pGAL4-CREB), a fulllength cDNA encoding rat CREB was amplified by PCR using RSV-CREB as a template, as previously described (Kida et al. 2002) , and the resulting PCR fragment encoding CREB was subcloned into the HindIII-BamHI sites of pM (CLONTECH, CA). To generate the b-galactosidase expression vector (pRc/ RSV-b-gal), a BamHI-HindIII fragment encoding bgalactosidase from pCH110 (Amersham, NJ) was subcloned into the corresponding restriction sites in pRc/RSV (Invitrogen, CA). The CRE-dependent luciferase reporter plasmid, pCRE-Luc, was purchased from STRATAGENE (CA).
Cell culture and transient transfection PC12 cells were maintained in Dulbecco's modified Eagle's (DMEM) medium (NISSUI, Japan) supplemented with 10% fetal bovine serum (JRH BIOSCIENCE, KS), 5% horse serum (JRH BIO-SCIENCE, KS), penicillin (100 U/ml), and streptomycin (100 lg/ml) at 37°C in 5% CO 2 . Cells were grown in 24-well plates and transiently transfected using the lipofectAMINE2000 reagent (Invitrogen, CA) according to the manufacture's instructions. Empty vector (pcDNA3) was used to standardize the total amount of DNA transfected (250 ng). Solutions of forskolin and ionomycin (Wako, Japan) were prepared in DMSO at 1 or 0.5 mM, respectively.
RNAi
To reduce the expression of target genes using siRNA, we targeted sequences in the middle of the open reading frames of GFP (AAGCTGACC-CTGAAGTTCATC, nucleotides 124 to 144), PLCc1 (AAACAACCGGCTCTTCGTCTT, nucleotides 2670-2690) and PLCc2 (AAGAAC-TCCAAGGACTTTGAG, nucleotides 229-249). We determined that these sequences are unique to the corresponding genes by a BLAST search of the GenBank TM database. The target sequence for PLCc1 was determined in a previous report (Patterson et al. 2002) . We constructed pSUPER-GFP, pSUPER-PLCc1 and pSUPER-PLCc2 using GeneTailor TM Site-Directed Mutagenesis System (Invitrogen, CA). We performed PCR using pSUPER (Brummelkamp et al. 2002) as a template and the following primers: pSUPER-GFP forward primer, GAGAGATGAACTTCAGGG-TCAGCTTTTTGGAAAAGCTTATCGATACC-G, pSUPER-GFP reverse primer, TTGAAGA TGAACTTCAGGGTCAGCGGGATCTGTGG-TCTCATACAG, pSUPER-PLCc1 forward primer, GAGAAAGACGAAGAGCCGGTTGTTT TTTGGAAAAGCTTATCGATACCG, pSU-PER-PLCc1 reverse primer, TTGAAAAGACG AAGAGCCGGTTGTGGGATCTGTGGTCTC-ATACAG, pSUPER-PLCc2 forward primer, GAGACTCAAAGTCCTTGGAGTTCTTTTTG GAAAAGCTTATCGATACCG, pSUPER-PLCc2 reverse primer, TTGAACTCAAAGTCCTTGG AGTTCGGGATCTGTGGTCTCATACAG. The resultant PCR fragment was self-ligated to generate a pSUPER vector containing the target sequence of GFP, PLCc1 or PLCc2. As described above, pSUPER vectors were transiently transfected into cells that were analyzed 72 h later.
Western blotting
Seventy-two hours after the transfection, cells were treated with forskolin (1 lM) or ionomycin (0.5 lM). 10 min later, whole cell extracts were prepared in SDS sample buffer (50 mM Tris-HCl (pH 6.8), 2.4% (w/v) SDS, 14.8% (v/v) 2-mercapt ethanol, 1% (w/v) Bromophenol Blue). Proteins were separated by electrophoresis through 5 or 10% SDS-polyacrylamide gels to detect CREB or PLCcs, respectively. Western blotting using antiphospho-CREB (Ser133) antibody, anti-CREB anitbody (1:1000; Cell Signaling, MA), antiPLCc2 antibody (1:1000; Santa Cruz, CA), anti-atubulin antibody (1:1000; Santa Cruz, CA) or antimyc antibody (1:1000; CLONTECH, CA) were performed as previously described (Hosoda et al. 2004) . Following signal development with Amersham's ECL plus systems (Amersham, NJ), membranes were analyzed by the Lumi-imager TM chemiluminescence detection system (Roche Diagnostics, Basel). The amount of total protein or CREB in each lane was confirmed to be comparable by reprobing with anti-a-tubulin or anti-CREB antibody, respectively.
Reporter assay
Seventy-two hours after transfection, cells were treated with forskolin (1 lM) or ionomycin (0.5 lM) 1.5 or 3.0 h prior to the reporter assay, respectively. Luciferase and b-galactosidase activities were then measured as previously described (Hosoda et al. 2004) . pRc/RSV-b-gal (100 ng) was co-transfected as a control for transfection efficiency. Luciferase activity was normalized to bgalactosidase activity. All reporter assays were performed in triplicate in three independent experiments. Each value represents the mean ± SD.
Results
siPLCc1 and siPLCc2 reduce PLCc1 or PLCc2 expression, respectively, in PC12 cells
To examine the role of PLCc in the activation of CREB in vivo, we employed RNA interference (RNAi) to reduce the expression of endogenous PLCc1 and 2. To do so, we used vectors (pSU-PER-PLCc1 and pSUPER-PLCc2) that expressed short hairpin RNAs that targeted PLCc1 or PLCc2 (siPLCc1 or siPLCc2, respectively) from the human H1 promoter. siPLCc1 and siPLCc2 targeted nucleotides 2670-2690 or 229-249 3¢ to the initiation codon of the corresponding mRNA, respectively. We characterized the ability of siPLCc1 and siPLCc2 to reduce the expression of PLCc1 and 2, using siGFP as a negative control. Importantly, a previous report has shown that both PLCc1 and PLCc2 are expressed and functional in PC12 cells (Patterson et al. 2002) . We first transiently transfected pmyc-PLCc1 with pSU-PER, pSUPER-GFP, pSUPER-PLCc1 or pSU-PER-PLCc2 into PC12 cells and examined the expression level of exogenous PLCc1 (myc-PLCc1) by Western blot analysis. As shown in Figure 1a , Western analyses using anti-myc antibody revealed the nearly complete suppression of mycPLCc1 expression following transfection of the cells with pSUPER-PLCc1, but not with pSU-PER, pSUPER-GFP or pSUPER-PLCc2. We next transiently transfected pSUPER, pSUPER-GFP, pSUPER-PLCc1 or pSUPER-PLCc2 into PC12 cells and examined the expression of endogenous PLCc2 using anti-PLCc2 antibody. As shown in Figure 1b , Western analyses also revealed the nearly complete suppression of PLCc2 expression following transfection of the cells with pSUPER-PLCc2, but not with pSUPER, pSU-PER-GFP or pSUPER-PLCc1. Importantly, probing of the same Western blots with control anti-a-tubulin antibody revealed the presence of comparable amounts of extracted proteins in each lane (Figure 1a and b) . These data indicate that siPLCc1 and siPLCc2 reduce the expression of PLCc1 or PLCc2, respectively, in PC12 cells.
PLCc2 but not PLCc1 is required for phosphorylation of CREB at S133
We next examined the effects of knockdown of PLCc1 or PLCc2 expression by RNAi on the phosphorylation of CREB at S133 following the activation of cAMP or Ca 2+ signaling pathways. We transiently transfected pSUPER, pSUPER-GFP, pSUPER-PLCc1 or pSUPER-PLCc2 into PC12 cells and examined the levels of total CREB and S133-phosphorylated CREB using anti-CREB or phospho-CREB antibody, respectively. Treatment of the non-transfected cells with forskolin, which stimulates the cAMP signaling pathway, led to an increase in the level of phospho-CREB without affecting the level of total CREB (Figure 2a) . Transfection of cells with pSUPER, pSUPER-GFP or pSUPER-PLCc1 had no effect upon the phosphorylation of CREB mediated by forskolin treatment. In contrast, the transfection with pSUPER-PLCc2 inhibited forskolin-induced phosphorylation of CREB without affecting the level of total CREB. Figure 2b represents the relative CREB activation (ratio of phospho-CREB to total CREB), and confirms the results observed in Figure 2a . These results suggest that PLCc2 mediates the phosphorylation of CREB at S133 in response to activation of the cAMP signaling pathway.
We next examined the effects of knockdown of PLCcs on the phosphorylation of CREB mediated by activation of the Ca 2+ signaling pathway. Treatment of non-transfected cells with ionomycin, which increases the intracellular Ca 2+ concentration, led to an increase in CREB phosphorylation (Figure 2c, d) . Interestingly, transfection with pSUPER-PLCc2 but not pSUPER, pSUPER-GFP or pSUPER-PLCc1, completely abolished ionomycin-induced phosphorylation of CREB at S133 (Figure 2c and d) . These results indicate that PLCc2 is essential for the ionomycin-induced phosphorylation of CREB at S133.
PLCc2, but not PLCc1, is required for the activation of CRE-mediated transcription Previous reports have indicated that the activation of cAMP or Ca 2+ signaling pathways induces CRE-mediated transcription in PC12 cells (Sheng et al. 1991; Mark et al. 1995; Thompson et al. 1995; Impey et al. 1998) . To probe the role of PLCcs in CRE-mediated transcription induced by activation of the cAMP and Ca 2+ signaling pathways, we examined the effects of knockdown of the expression of PLCc1 and c2 in PC12 cells on this process. Cells were transiently transfected with Figure 2 . PLCc2 but not PLCc1 is required for phosphorylation of CREB at S133 following activation of cAMP and Ca 2+ signaling pathway in PC12 cells Cells were transiently transfected with the plasmids pSUPER, pSUPER-GFP, pSUPER-PLCc1 or pSUPERPLCc2 (5 ng), as indicated. Western blot analysis was performed using anti-phospho-CREB (Ser133) antibody. The amount of total CREB in each lane was confirmed to be comparable by reprobing with anti-CREB antibody. Cells were treated with forskolin (a, b) or ionomycin (c, d), as indicated. (b, d) The bar graphs show the ratio of phosphorylated CREB to total CREB, as estimated by densitometry from the Western blot of (a) and (c), respectively. Western blot assays were performed in four independent experiments. Each value represents the mean ± SD. a CRE-luciferase reporter construct in the absence or presence of individual plasmids pSUPER, pSUPER-GFP, pSUPER-PLCc1 or pSUPERPLCc2. Consistent with previous reports, the treatment of non-transfected cells with forskolin or ionomycin led to the activation of the CREdependent promoter (Figure 3a, b) . Cotransfection with pSUPER-PLCc2, but not pSUPER, pSUPER-GFP or pSUPER-PLCc1, reduced the activation of CRE-mediated transcription induced by treatment of the cells with forskolin or ionomycin. These results indicate that PLCc2, but not PLCc1, is necessary for maximal activation of CRE-mediated transcription induced by cAMP or Ca 2+ signaling pathways in PC12 cells.
PLCc2 but not PLCc1 is required for the activation of CREB-dependent transcription
PC12 cells express other members of the CREB/ ATF family in addition to CREB (D'Arcangelo et al. 1996; Ryu et al. 2002; Suzuki et al. 2002) . These factors bind to CRE and regulate CREmediated transcription in response to the modulation of various signal transduction cascades (Brindle and Montminy 1992; Livingstone et al. 1995; Chen et al. 1996; Shimomura et al. 1996; Yoshida et al. 2001; Yang et al. 2004) . To further understand the roles of PLCcs in the activation of CREB, we created a fusion of CREB with the GAL4-DNA binding domain (GAL4-CREB). A plasmid expressing GAL4-CREB was transiently cotransfected with the GAL4 reporter construct, in the presence or absence of individual plasmids pSUPER, pSUPER-GFP, pSUPER-PLCc1 or pSUPER-PLCc2. Treatment of cells with forskolin or ionomycin led to CREB-dependent activation of transcription from the GAL4-dependent promoter (Figure 4a, b) . Consistent with the results of Figure 3a , cotransfection with pSUPER-PLCc2, but not pSUPER, pSUPER-GFP or pSUPERPLCc1, inhibited CREB-dependent activation of the GAL4 promoter mediated by forskolin, indicating that PLCc2 is required for maximal activation of CREB-dependent transcription induced by cAMP signaling in PC12 cells. Interestingly, siPLCc2 completely suppressed CREB-dependent transcription induced by treatment of cells with ionomycin, suggesting that PLCc2 plays an essential role in the activation of CREB-dependent transcription in response to Ca 2+ signaling (Figure 4b) . These results suggest that PLCc2, but not PLCc1, mediates CREB activation in response to cAMP and Ca 2+ signaling in PC12 cells.
Discussion
Previous reports have suggested that PLCcs play important roles in the activation of CREB (Minichiello et al. 2002) . In this report, we have shown that siRNA-mediated knockdown of the expression of PLCc2, but not PLCc1, inhibited both the phosphorylation of CREB and the activation of CREB-dependent transcription. The phosphorylation of CREB and the induction of CREB-dependent transcription are both mediated by the activation of cAMP or Ca 2+ signaling pathways in PC12 cells. These results suggest that PLCc2 activates CREB through the phosphorylation of S133 in response to an increase in intracellular concentrations of cAMP or Ca 2+ in PC12 cells. Interestingly, siPLCc2 completely abolished the activation of CREB induced by treatment of cells with ionomycin, indicating that PLCc2 is essential for the activation of CREB by Ca 2+ signaling in PC12 cells. A previous report has demonstrated that PLCc2 amplifies the Ca 2+ signaling (Patterson et al. 2002; Nishida et al. 2003) . Additionally, numerous studies have indicated that an increase in the intracellular Ca 2+ concentration leads to activation of CaMKs and PKCs (Nishizuka 1988; Schulman et al. 1992; Hook and Means 2001; Elgersma et al. 2004; Griffith 2004) . Several CaMKs, including CaMKIV and CaMKII, are known to function as CREB kinases, whereas PKCs activate MAPK, whose activation in turn leads to the activation of CREB kinases (Sheng et al. 1991; Brindle and Montminy 1992; Sassone-Corsi 1995; Xie and Rothstein 1995; Bito et al. 1996; Schonwasser et al. 1998; Shaywitz and Greenberg 1999) . These previ- ous findings suggest that PLCc2 potentiates the Ca 2+ response, resulting in an increase in the phosphorylation of CREB by downstream CREB kinases in the Ca 2+ signaling pathway. siPLCc2 did not completely abolish the activation of CREB mediated by cAMP signaling. cAMP directly activates PKA, which is known to function as a CREB kinase (Gonzalez and Montminy 1989; Brindle and Montminy 1992; Sassone-Corsi 1995) . Importantly, a recent study has shown that PKA stimulates PLCc2 activity, suggesting that PLCc2 functions as a downstream signal transducer of the cAMP signaling pathway (Yu et al. 1996) . Therefore, PKA is thought to activate CREB through both direct and indirect mechanisms: directly via phosphorylation of CREB by PKA itself and indirectly via the activation of PLCc2.
Activation of the lipase activity of PLC c2 leads to an increase in the IP 3 concentration, leading subsequently to an increase in the Ca 2+ concentration (Berridge 1993; Carpenter and Ji 1999; Patterson et al. 2002; Nishida et al. 2003) . However, the treatment of PC12 cells with forskolin increases the intracellular concentration of cAMP but not Ca 2+ (data not shown), suggesting that PLCc2 mediates the phosphorylation of CREB in a Ca 2+ -independent manner following the activation of the cAMP signaling pathway. Importantly, PLCcs contain functional domains that interact with other signal transducers (Berridge 1993; Carpenter and Ji 1999; Patterson et al. 2002) . Indeed, previous studies have suggested that PLCcs function in both a lipase-dependent and lipase-independent manner (Smith et al. 1994; Patterson et al. 2002; Nishida et al. 2003) . Therefore, in response to the activation of cAMP signaling, PLCc2 might lead to the phosphorylation of CREB at S133 in a lipase-independent manner, through the activation of signaling pathways by distinct mechanisms such as the modulation of protein-protein interaction.
A previous report has shown that both PLCc1 and PLCc2 are expressed in PC12 cells and function as modulators of the Ca 2+ response (Patterson et al. 2002) . In addition, numerous studies have demonstrated that PLCc2 exhibits comparable function as a signal transducer with PLCc1 (Emori et al. 1989; Sultzman et al. 1991; Rhee and Choi 1992; Carpenter and Ji 1999; Rebecchi and Pentyala 2000; Patterson et al. 2002) . However, we have here demonstrated distinct roles for PLCc2 and PLCc1 in the activation of CREB in PC12 cells. Interestingly, several reports have shown that PLCc1 and PLCc2 differ in subcellular localization in RBL-2H3 tumor mast cells and that collagen signal transduction stimulates tyrosine phosphorylation of PLCc2, but not PLCc1, in human platelets (Blake et al. 1994; Barker et al. 1998) . These previous findings suggest that PLCc2 is activated by cAMP or Ca 2+ signaling or activates its downstream signaling cascades, in PC12 cells in a different manner from PLCc1.
